Whereas the low levels of AXL expression in some of the cohorts may explain the lack of clinically meaningful activity by EnaV, no objective responses were observed in patients in the sarcoma cohort despite having the highest median percentage of AXL-positive tumor cells. The gene discussed is AXL; the disease is neoplasm.